download chevron-down chevron-right chevron-with-circle-down chevron-with-circle-up check circle-with-minus circle-with-plus export help-with-circle inbox link mail old-phone star-outlined star user v-card close close close Back to top
Top Top of Content

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

eCQMs for 2017 Performance Period

Last updated: May 16, 2019

CMS Measure ID: CMS144v5
Version: 5
NQF Number: 2908e
NQF Number: 2908
Measure Description:

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge
Initial Population:

All patients aged 18 years and older with a diagnosis of heart failure
Denominator Statement:

Equals Initial Populationinfo-icon with a current or prior LVEF < 40%
Denominator Exclusions:

None
Numerator Statement:

Patients who were prescribed beta-blocker therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge
Numerator Exclusions:

Not Applicable
Denominator Exceptions:

Documentation of medical reason(s) for not prescribing beta-blocker therapy (eg, low blood pressure, fluid overload, asthma, patients recently treated with an intravenous positive inotropic agent, allergy, intolerance, other medical reasons)

Documentation of patient reason(s) for not prescribing beta-blocker therapy (eg, patient declined, other patient reasons)

Documentation of system reason(s) for not prescribing beta-blocker therapy (eg, other reasons attributable to the healthcare system)
Measure Steward: PCPI(R) Foundation (PCPI[R])
Domain: Effective Clinical Care
Next Version:
CMS144v6
Previous Version:
CMS144v4
Measure Scoring: Proportion
Measure Type: Process
Improvement Notation:

Higher score indicates better quality
Guidance:

LVEF < 40% corresponds to qualitative documentation of moderate dysfunction or severe dysfunction.

To satisfy this measure, it must be reported for all heart failure patients at least once during the measurement period if seen in the outpatient setting. If the patient has an eligible inpatient discharge during the measurement period, as defined in the measure logic, it is expected to be reported at each hospital discharge.

Beta-blocker therapy:

-For patients with prior LVEF < 40%, beta-blocker therapy should include bisoprolol, carvedilol, or sustained release metoprolol succinate.

The requirement of Count >=2 of Encounter, Performed is to establish that the eligible professionalinfo-icon has an existing relationship with the patient.
Quality ID: 008
High Priority Measure: No
Data Submission Method: EHR,Registry
Specialty Measure Set: Cardiology,Hospitalists,General Practice/Family Medicine

Specifications

Release Notes

Header

  • ​Updated Copyright.

    Section: Copyright

    Source: Annual Update

  • Updated Disclaimer.

    Section: Disclaimer

    Source: Measure Lead

  • Incremented eMeasure Version number.

    Section: eMeasure Version number

    Source: Annual Update

  • Updated Measure Developerinfo-icon.

    Section: Measure Developer

    Source: Measure Lead

  • Updated Measure Stewardinfo-icon.

    Section: Measure Steward

    Source: Measure Lead

  • Updated NQFinfo-icon Number to '2908'. As of February 2016, this measure is endorsed by NQF as an eMeasure and has been assigned a new NQF number.

    Section: NQF Number

    Source: Measure Lead

Logic

  • Replaced datatypes 'Diagnosis, Active; Diagnosis, Inactive; Diagnosis, Resolved' with the re-specified 'Diagnosis' datatype to conform to QDM 4.2 changes.

    Section: Denominatorinfo-icon

    Source: QDM Standards

  • Replaced datatypes 'Diagnosis, Active; Diagnosis, Inactive; Diagnosis, Resolved' with the re-specified 'Diagnosis' datatype to conform to QDM 4.2 changes.

    Section: Denominator Exceptionsinfo-icon

    Source: QDM Standards

  • Replaced datatypes 'Diagnosis, Active; Diagnosis, Inactive; Diagnosis, Resolved' with the re-specified 'Diagnosis' datatype to conform to QDM 4.2 changes.

    Section: Initial Populationinfo-icon

    Source: QDM Standards

  • Replaced datatypes 'Diagnosis, Active; Diagnosis, Inactive; Diagnosis, Resolved' with the re-specified 'Diagnosis' datatype to conform to QDM 4.2 changes.

    Section: QDM Data Elements

    Source: QDM Standards

Value Setinfo-icon

  • Value set Allergy to Beta Blocker Therapy (2.16.840.1.113883.3.526.3.1177): Deleted 1 SNOMEDCT code (407577009).

    Section: None

    Source: None

  • Value set Asthma (2.16.840.1.113883.3.526.3.362): Added 9 SNOMEDCT codes (707445000, 707446004, 707447008, 708038006, 708090002, 708093000, 708094006, 708095007, 708096008) and deleted 7 SNOMEDCT codes (233681001, 233685005, 266364000, 427354000, 57546000, 59327009, 91340006).

    Section: None

    Source: None

  • Value set Beta Blocker Therapy (2.16.840.1.113883.3.526.3.1174): Added 16 RXNORM codes and deleted 4 RXNORM codes (856412, 896974, 896975, 896976).

    Section: None

    Source: None

  • Value set Beta Blocker Therapy Ingredient (2.16.840.1.113883.3.526.3.1493): Deleted 1 RXNORM code (689716).

    Section: None

    Source: None

  • Value set Medical Reason (2.16.840.1.113883.3.526.3.1007): Deleted 1 SNOMEDCT code (161590003).

    Section: None

    Source: None

  • Value set Patient Reason (2.16.840.1.113883.3.526.3.1008): Deleted 1 SNOMEDCT code (5015009).

    Section: None

    Source: None

External Resources